Epidemiology and economic burden of "serious" adverse drug reactions: Real-world evidence research based on pharmacovigilance data.
Fiche publication
Date publication
décembre 2021
Journal
Therapie
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NERICH Virginie
Tous les auteurs :
Tissot M, Valnet-Rabier MB, Stalder T, Limat S, Davani S, Nerich V
Lien Pubmed
Résumé
Serious adverse drug reactions account for 3.6% of French hospital admissions. Of these, 48.5% are, at least potentially, preventable. The first aim of post-marketing pharmacovigilance is to detect adverse drug reactions as a safety signal to improve patients' safety. Thus, this study describes the epidemiology of "serious" adverse drug reactions reported between 2015 and 2018 to a regional pharmacovigilance centre and assesses their economic burden.
Mots clés
Adverse drug reaction, Drugs, Economic burden of disease, Epidemiology, Pharmacovigilance
Référence
Therapie. 2021 Dec 15;: